Johnson & Johnson Reports Q4 and Full-Year 2021 Results

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength...

Related Keywords

South Africa ,United States ,Canada ,Johnson ,Consumer Health Business ,Digital Surgery Solutions ,European Commission Approves ,Microsoft ,Paliperidone Palmitate ,Maintenance Treatment ,Multiple Myeloma After First ,Conditional Marketing Authorisation ,First Treatment Approved ,Advanced Nonsmall Cell Lung Cancer ,Mutations After Failure ,Booster Shot Authorized ,Emergency Use ,Health Organization Strategic Advisory Group ,Interim Recommendation Supports Use ,Booster Shot ,Two New Indications ,Help Prevent ,Treat Blood Clots ,Seeks Approval ,Fixed Duration Regimen ,Untreated Chronic Lymphocytic Leukaemia ,Submits Biologics License Application ,Refractory Multiple ,Johnson Announces Plans ,Accelerate Innovation ,Serve Patients ,Unlock Value ,Separate Consumer Health ,Johnson Appoints Senior Leaders ,Further Enable ,Digital Surgery ,Administered Six Months After Two Dose Regimen ,Shows Substantial Increase ,Johnson Enters ,Most Vulnerable People ,Novel Humanitarian ,Johnson Amp ,